Overview
Agenda
Faculty
View Archive

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant by Portola Pharmaceuticals, Inc.

Cases and Conversations: Clinical Considerations for the Use of DOAC Reversal Agents

Cases and Conversations: Clinical Considerations for the Use of DOAC Reversal Agents


Live Interactive Webcast

Monday, October 5, 2020

7:00pm-8:30pm EDT

 

Cases and Conversations: Clinical Considerations for the Use of DOAC Reversal Agents

Program Overview

The field of direct oral anticoagulant (DOAC) reversal agents is relatively new. A known adverse event among all anticoagulation therapies is increased risk of bleeding following therapy. Any bleeding patient on an anticoagulant should be risk-stratified based on hemodynamic instability, source of bleeding, and degree of blood loss.

It is vital for clinicians to be able to identify patients at risk for severe bleeding episodes due to oral anticoagulant therapy and understand when to implement reversal agents based on guidelines and protocols. This activity, Cases and Conversations™: Clinical Considerations for the Use of DOAC Reversal Agents, and will cover the clinical need for reversal agents, current guidelines on reversal therapies, the role of clinicians across several disciplines, and the clinical implications within each therapeutic area. Clinical experts will then discuss a range of patient cases that will bring together the elements of clinical decision making when implementing reversal agents in practice.

Benefits of Attending

  • Gain insights into the importance of addressing bleeding risks following anticoagulant therapy
  • Improve knowledge regarding the integration of new treatment options to reduce the risk of bleeding
  • Hear how experts approach challenging patient scenarios that you frequently encounter in your practice
  • Network with your peers to share best practices

Acknowledgement of Commercial Support

This activity is supported by an educational grant by Portola Pharmaceuticals, Inc.

Target Audience

This educational activity is directed toward cardiologists who treat patients at risk of severe bleeding episodes following anticoagulant therapy. Cardiologists, emergency physicians, and other healthcare professionals interested in the treatment of bleeding are invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Identify factors associated with high risk of severe bleeding in patients using DOAC therapy
  • Evaluate the efficacy and safety of reversal agents for DOAC therapy
  • Discuss application of institutional best practices for reversal of DOAC therapy in patients with, or at high risk of, severe bleeding

Program Chair

Geoffrey Barnes
Geoffrey Barnes, MD, MSc
Assistant Professor of Internal Medicine
Frankel Cardiovascular Center
University of Michigan Medical School
Ann Arbor, MI



Register

You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information


Registration Information


Professional Information


Specialties*

Submit
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
  12345
6789101112
13141516171819
20212223242526
27282930
Filter By